ArticleDiscover oncology2026
Radiotherapy-based multimodal treatment in advanced NSCLC with spinal infiltration: a case series of seven unfavorable patients.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLocally advanced non-small cell lung cancer (LA-NSCLC) with spinal invasion presents a rare but challenging clinical scenario. Radical surgical approaches, though potentially curative, are often not feasible due to comorbidities, advanced age, poor performance status or technical inoperability. In this setting, the optimal multimodal treatment strategy including radiotherapy (RT) and systemic treatment remains to be fully defined.
methodsWe retrospectively analyzed seven patients with stage III/IV NSCLC and radiologically confirmed spinal invasion treated between 2023 and 2025. Treatment modalities included radiotherapy, systemic therapy, and surgical procedures. Patients were retrospectively stratified using the prognostic scoring system proposed by Lei et al. to assess clinical outcomes by risk group.
resultsFour patients were classified as low-risk (score 4-5), and three as intermediate-risk (score 6-7); no patients fell into the high-risk category. Two low-risk patients showed favorable outcomes, including long-term survival and disease stability, while two succumbed to local progression. All intermediate-risk patients died within 5-13 months due to disease progression. Radical surgery was not feasible in any case. Timely treatment initiation and multidisciplinary care were associated with improved outcomes in selected patients.
conclusionRT-based multimodal treatment appears feasible in selected unfavorable patients with advanced NSCLC and spinal infiltration who are not candidates for radical surgery. The prognostic score can help in risk stratification, though timely therapeutic decision-making is equally critical. However, due to the small sample size, the impact on survival remains uncertain and requires validation in larger studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.